Publication Venue For

  • Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinoma.  17:399-406. 2018
  • Image-guided brachytherapy for cervical cancer: Analysis of D2 cc hot spot in three-dimensional and anatomic factors affecting D2 cc hot spot inorgans at risk.  203-209. 2014
  • Response to Drs Rogers, Hayes, and Demanes.  523. 2014
  • American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer.  11:68-75. 2012
  • American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy.  11:47-52. 2012
  • Bi- and tri-exponential fitting to TG-43 radial dose functions of¬†brachytherapy sources based on a genetic algorithm 2009
  • Dosimetric comparison of IMRT to HDR intracavitary brachytherapy for cervical cancer.  6:84-84. 2007
  • Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.  5:49-55. 2006
  • Image-based intracavitary brachytherapy in the treatment of inoperable uterine cancer: Individual dose specification at specific anatomical sites.  4:286-290. 2005
  • Radiography-based treatment planning compared with computed tomography (CT)-based treatment planning for intracavitary brachytherapy in cancer of the cervix: Analysis of dose-volume histograms.  2:200-206. 2003
  • Postoperative intravaginal brachytherapy for endometrial cancer: Dosimetric analysis of vaginal colpostats and cylinder applicators.  1:138-144. 2002
  • ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer.  16:266-276.
  • International Standard Serial Number (issn)

  • 1538-4721
  • Electronic International Standard Serial Number (eissn)

  • 1873-1449